Deborah A. O’Neil

Chief Executive Officer at NovaBiotics Ltd.

53 year

Consumer Services

Health Technology

Miscellaneous

Profile

Deborah A.
O’Neil is the founder of NovaBiotics Ltd., a company founded in 2004.
She holds the title of Chief Executive & Scientific Officer at NovaBiotics Ltd.
Currently, Dr. O’Neil is a Trustee at Leap Confronting Conflict, a position she started in 2017.
Dr. O’Neil has an educational background, having studied at University College London where she obtained an undergraduate degree and a doctorate.

Deborah A. O’Neil active positions

Companies	Position	Start
NovaBiotics Ltd. NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.	Chief Executive Officer	31/07/2004
Leap Confronting Conflict Leap Confronting Conflict Investment Trusts/Mutual FundsMiscellaneous Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.	Director/Board Member	05/07/2017

All active positions of Deborah A. O’Neil

Training of Deborah A. O’Neil

University College London

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Deborah A. O’Neil's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
NovaBiotics Ltd. NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.	Health Technology
Leap Confronting Conflict Leap Confronting Conflict Investment Trusts/Mutual FundsMiscellaneous Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.	Miscellaneous